Cellular oncogenes and carcinogenesis

Molecular Carcinogenesis and the Molecular Biology of Human Cancer

Volumn , Issue , 2005, Pages 103-130

  Zarbl, Helmut ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449133654     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (76)

1. Huebner, R.J. and Todaro, G.J. Oncogenes of RNA tumor viruses as determinants of cancer. Proc. Natl. Acad. Sci. USA, 64: 1087-1094, 1969.
2. Stehelin, D., Varmus, H.E., Bishop, J.M., and Vogt, P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature, 260: 170-173, 1976.
3. Bishop, J.M. Viruses, genes, and cancer. II. Retroviruses and cancer genes. Cancer, 55: 2329-2333, 1985.
4. Varmus, H. Retroviruses. Science, 240: 1427-1435, 1988.
5. Jonkers, J. and Berns, A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys. Acta, 1287: 29-57, 1996.
6. Nusse, R. Insertional mutagenesis in mouse mammary tumorigenesis. Curr. Top. Microbiol. Immunol., 171: 43-65, 1991.
7. Tsichlis, P.N., Strauss, P.G., and Hu, L.F. A common region for proviral DNA integration in MoMuLV-induced rat thymic lymphomas. Nature, 302: 445-449, 1983.
8. Lazo, P.A., Lee, J.S., and Tsichlis, P.N. Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas. Proc. Natl. Acad. Sci. USA, 87: 170-173, 1990.
9. Neil, J.C. and Cameron, E.R. Retroviral insertion sites and cancer: Fountain of all knowledge? Cancer Cell, 2: 253-255, 2002.
10. Weinberg, R.A. A molecular basis of cancer. Sci. Am., 249: 126-142, 1983.
11. Gibbs, W.W. Untangling the roots of cancer. Sci. Am., 289: 56-65, 2003.
12. Barbacid, M., Lamballe, F., Pulido, D., and Klein, R. The trk family of tyrosine protein kinase receptors. Biochim. Biophys. Acta, 1072: 115-127, 1991.
13. Pane, F., Intrieri, M., Quintarelli, C., Izzo, B., Muccioli, G.C., and Salvatore, F. BCR/ABL genes and leukemic phenotype: From molecular mechanisms to clinical correlations. Oncogene, 21: 8652-8667, 2002.
14. Druker, B.J. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol. Med., 8: S14-S18, 2002.
15. Boveri, T. Zur Frage der Enstehung maligner Tumoren. Gustav Fisher, Jena, 1914.
16. Momand, J. and Zambetti, G.P. Mdm-2: “big brother” of p53. J. Cell. Biochem., 64: 343-352, 1997.
17. Albertson, D.G. and Pinkel, D. Genomic microarrays in human genetic disease and cancer. Hum. Mol. Genet., 2003.
18. Balmain, A. and Brown, K. Oncogene activation in chemical carcinogenesis. Adv. Cancer. Res., 51: 147-182, 1988.
19. Blume-Jensen, P. and Hunter, T. Oncogenic kinase signalling. Nature, 411: 355-365, 2001.
20. Malumbres, M. and Barbacid, M. RAS oncogenes: The first 30 years. Nat. Rev. Cancer, 3: 459-465, 2003.
21. Barbacid, M. ras oncogenes: Their role in neoplasia. Eur. J. Clin. Invest., 20: 225-235, 1990.
22. Barbacid, M. ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
23. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53: 549-554, 1988.
24. Bartram, C.R. Mutations in ras genes in myelocytic leukemias and myelodysplastic syndromes. Blood Cells, 14: 533-538, 1988.
25. Fasano, O., Aldrich, T., Tamanoi, F., Taparowsky, E., Furth, M., and Wigler, M. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc. Natl. Acad. Sci. USA, 81: 4008-4012, 1984.
26. Shih, T.Y., Hattori, S., Clanton, D.J., Ulsh, L.S., Chen, Z.Q., Lautenberger, J.A., and Papas, T.S. Structure and function of p21 ras proteins. Gene Amplif. Anal., 4: 53-72, 1986.
27. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks, M.W., and Weinberg, R.A. Creation of human tumour cells with defined genetic elements. Nature, 400: 464-468, 1999.
28. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O’Hagan, R., Pantginis, J., Zhou, H., Horner, J.W., 2nd, Cordon-Cardo, C., Yancopoulos, G.D., and DePinho, R.A. Essential role for oncogenic Ras in tumour maintenance. Nature, 400: 468-472, 1999.
29. Duesberg, P.H. Are cancers dependent on oncogenes or on aneuploidy? CancerGenet. Cytogenet., 143: 89-91, 2003.
30. Duesberg, P.H. Oncogenes and cancer. Science, 267: 1407-1408, 1995.
31. Sonneschein, C. and Soto, A. The Society of Cells: Cancer and Control of Cell Proliferation. BIOS Scientific Publishers, Ltd, Oxford UK and Springer Verlag, New York, 1999.
32. Finney, R.E. and Bishop, J.M. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science, 260: 1524-1527, 1993.
33. Cha, R.S., Thilly, W.G., andZarbl, H. N-nitroso-N -methylurea-induced rat mammary tumors arise from cells with preexisting oncogenic Hras1s gene mutations. Proc. Natl. Acad. Sci. USA, 91: 3749-3753, 1994.
34. Zhang, Z., Wang, Y., Vikis, H.G., Johnson, L., Liu, G., Li, J., Anderson, M.W., Sills, R.C., Hong, H.L., Devereux, T.R., Jacks, T., Guan, K.L., and You, M. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet., 29: 25-33, 2001.
35. Diaz, R., Ahn, D., Lopez-Barcons, L., Malumbres, M., Perez de Castro, I., Lue, J., Ferrer-Miralles, N., Mangues, R., Tsong, J., Garcia, R., Perez-Soler, R., and Pellicer, A. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res., 62: 4514-4518, 2002.
36. Bargmann, C.I., Hung, M.C., and Weinberg, R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell, 45: 649-657, 1986.
37. Yarden, Y. and Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2: 127-137, 2001.
38. Mercer, K.E. and Pritchard, C.A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta, 1653: 25-40, 2003.
39. Rowley, J.D. Chromosome translocations: Dangerous liaisons revisited. Nat. Rev. Cancer, 1: 245-250, 2001.
40. Rabbitts, T.H. Chromosomal translocations in human cancer. Nature, 372: 143-149, 1994.
41. Nowell, P.C. The clonal evolution of tumor cell populations. Science, 194: 23-28, 1976.
42. Schimke, R.T. Gene amplification, drug resistance, and cancer. Cancer Res., 44: 1735-1742, 1984.
43. Hahn, PJ. Molecular biology of double-minute chromosomes. Bioessays, 15: 477-484, 1993.
44. Brodeur, G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer, 3: 203-216, 2003.
45. Ideker, T., Galitski, T., and Hood, L. A new approach to decoding life: Systems biology. Annu. Rev. Genomics Hum. Genet., 2: 343-372, 2001.
46. Pawson, T. and Nash, P. Assembly of cell regulatory systems through protein interaction domains. Science, 300: 445-452, 2003.
47. Aaronson, S.A. Growth factors and cancer. Science, 254: 1146-1153, 1991.
48. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol., 31: 637-643, 1999.
49. Roberts, A.B. and Wakefield, L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. USA, 100: 8621-8623, 2003.
50. Taipale, J. and Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature, 411: 349-354, 2001.
51. Neel, B.G., Gu, H., and Pao, L. The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci., 28: 284-293, 2003.
52. Rodien, P., Ho, S.C., Vlaeminck, V., Vassart, G., and Costagliola, S. Activating mutations of TSH receptor. Ann. Endocrinol. (Paris), 64: 12-16, 2003.
53. Boudny, V. and Kovarik, J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma, 49: 349-355, 2002.
54. Pawson, T. Regulation and targets of receptor tyrosine kinases. Eur. J. Cancer, 38 (Suppl 5): S3-S10, 2002.
55. Resh, M.D. Regulation of cellular signalling by fatty acid acylation and prenylation of signal transduction proteins. Cell Signal., 8: 403-412, 1996.
56. Dinsmore, C.J. and Bell, I.M. Inhibitors of farnesyltransferase and geranylgeranyltransferase-I for antitumor therapy: Substrate-based design, conformational constraint and biological activity. Curr. Top. Med. Chem., 3: 1075-1093, 2003.
57. Dasgupta, B. and Gutmann, D.H. Neurofibromatosis 1: Closing the GAP between mice and men. Curr. Opin. Genet. Dev., 13: 20-27, 2003.
58. Malumbres, M. and Barbacid, M. To cycle or not to cycle: A critical decision in cancer. Nat. Rev. Cancer, 1: 222-231, 2001.
59. Noda, M. Structures and functions of the K rev-1 transformation suppressor gene and its relatives. Biochim. Biophys. Acta, 1155: 97-109, 1993.
60. Chang, F., Steelman, L.S., Shelton, J.G., Lee, J.T., Navolanic, P.M., Blalock, W.L., Franklin, R., and McCubrey, J.A. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int. J. Oncol., 22: 469-480, 2003.
61. Su, B. and Karin, M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr. Opin. Immunol., 8: 402-411, 1996.
62. Vivanco, I. and Sawyers, C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer, 2: 489-501, 2002.
63. Staal, S.P. and Hartley, J.W. Thymic lymphoma induction by the AKT8 murine retrovirus. J. Exp. Med., 167: 1259-1264, 1988.
64. Giles, R.H., van Es, J.H., and Clevers, H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta, 1653: 1-24, 2003.
65. Polakis, P. Wnt signaling and cancer. Genes Dev., 14: 1837-1851, 2000.
66. Dean, M. Towards a unified model of tumor suppression: Lessons learned from the human patched gene. Biochim. Biophys. Acta, 1332: M43-M52, 1997.
67. Darnell, J.E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer, 2: 740-749, 2002.
68. Forrest, D. and Curran, T. Crossed signals: Oncogenic transcription factors. Curr. Opin. Genet Dev., 2: 19-27, 1992.
69. Vogt, P.K. Jun, the oncoprotein. Oncogene, 20: 2365-2377, 2001.
70. Pelengaris, S., Khan, M., and Evan, G. c-MYC: More than just a matter of life and death. Nat. Rev. Cancer, 2: 764-776, 2002.
71. Ruggero, D. and Pandolfi, P.P. Does the ribosome translate cancer? Nat. Rev. Cancer, 3: 179-192, 2003.
72. Zhu, J., Chen, Z., Lallemand-Breitenbach, V., and de The, H. How acute promyelocytic leukaemia revived arsenic. Nat. Rev. Cancer, 2: 705-713, 2002.
73. He, L.Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R.P., Jr., Rifkind, R.A., Marks, P.A., Richon, V.M., and Pandolfi, P.P. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest., 108: 1321-1330, 2001.
74. Weston, A.D., Blumberg, B., and Underhill, T.M. Active repression by unliganded retinoid receptors in development: Less is sometimes more. J. Cell Biol., 161: 223-228, 2003.
75. Evan, G.I. and Vousden, K.H. Proliferation, cell cycle and apoptosis in cancer. Nature, 411: 342-348, 2001.
76. Cory, S. and Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2: 647-656, 2002.